In this three-part series, Michael Parisi, Lumanity’s Chief Client Officer, explores Lumanity’s Value Inflection Point framework with leaders from across biopharma. Each session will dive into the real-world insights from executives who have navigated these pivotal moments—from early asset strategy to launch execution and post-market optimization.
In part one, we explore how early-stage decisions have an outsized impact on long-term success and how engaging early at the first Value Inflection Point to define a differentiated value proposition, anticipate market and regulatory shifts, and embed patient insights can set the stage for sustained success.
Moderator:
- Michael Parisi, Chief Client Officer, Lumanity
- Joe Guidi, VP, Medical Early Differentiation and Pipeline, Bristol Myers Squibb
